{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"14.7","upperLimit":"94.7","value":"60.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"description":"The proportion of subjects evaluated as response (CR + PR) was calculated.\n\nPR (SWOG) requires the followings:\n\n1. Decline in myeloma protein of ≥25%-\\<74% in serum myeloma protein\n2. Reduction in 24h urinary myeloma protein of ≥25%-\\<89%\n3. No increase in skeletal destruction\n4. Serum calcium within normal range","dispersionType":"95% Confidence Interval","groups":[{"description":"SyB L-0501 (150 mg/m2/day) will be administered by intravenous drip infusion for 60 min for 2 consecutive days and the course will be observed for the next 26 days. This is taken as one cycle and administration is repeated for 2-9 cycles (when a plateau is not reached after nine cycles, administration of up to an additional three cycles for a maximum of 12 cycles is possible. Prednisolone (60 mg/m2/day) will be administered orally for 4 consecutive days and the course will be observed for the next 24 days.","id":"OG000","title":"SyB L-0501 + Prednisolone"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 36 weeks","title":"Response Rate (Based on the Modified SWOG Criteria)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}